Artículos de revistas sobre el tema "Bone, Paget, osteoclast, p62"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 28 mejores artículos de revistas para su investigación sobre el tema "Bone, Paget, osteoclast, p62".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Hiruma, Yuko, Noriyoshi Kurihara, Diane F. Jelinek y David Roodman. "Increased Signaling through p62 in the Marrow Microenvironment Increases Myeloma Cell Growth and Osteoclast Formation". Blood 112, n.º 11 (16 de noviembre de 2008): 642. http://dx.doi.org/10.1182/blood.v112.11.642.642.
Texto completoLayfield, R., J. R. Cavey, D. Najat, J. Long, P. W. Sheppard, S. H. Ralston y M. S. Searle. "p62 mutations, ubiquitin recognition and Paget's disease of bone". Biochemical Society Transactions 34, n.º 5 (1 de octubre de 2006): 735–37. http://dx.doi.org/10.1042/bst0340735.
Texto completoIshizuka, Fumito, Jolene Windle, David Roodman y Noriyoshi Kurihara. "p62 as a Therapeutic Target for Myeloma Cell Growth and Osteoclast Formation." Blood 114, n.º 22 (20 de noviembre de 2009): 2857. http://dx.doi.org/10.1182/blood.v114.22.2857.2857.
Texto completoLayfield, Robert. "The molecular pathogenesis of Paget disease of bone". Expert Reviews in Molecular Medicine 9, n.º 27 (septiembre de 2007): 1–13. http://dx.doi.org/10.1017/s1462399407000464.
Texto completoSundaram, Kumaran, Srinivasan Shanmugarajan, D. Sudhaker Rao y Sakamuri V. Reddy. "Mutant p62P392L Stimulation of Osteoclast Differentiation in Paget's Disease of Bone". Endocrinology 152, n.º 11 (30 de agosto de 2011): 4180–89. http://dx.doi.org/10.1210/en.2011-1225.
Texto completoLayfield, Robert y Mark S. Searle. "Disruption of ubiquitin-mediated processes in diseases of the brain and bone". Biochemical Society Transactions 36, n.º 3 (21 de mayo de 2008): 469–71. http://dx.doi.org/10.1042/bst0360469.
Texto completoHiruma, Yuko, Tadashi Honjo, Diane F. Jelinek, Jolene J. Windle, Jaekyoon Shin, G. David Roodman y Noriyoshi Kurihara. "Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation". Blood 113, n.º 20 (14 de mayo de 2009): 4894–902. http://dx.doi.org/10.1182/blood-2008-08-173948.
Texto completoSultana, Melanie A., Carmel Cluning, Wai-Sin Kwong, Nicole Polain, Nathan J. Pavlos, Thomas Ratajczak, John P. Walsh, Jiake Xu y Sarah L. Rea. "The SQSTM1/p62 UBA domain regulates Ajuba localisation, degradation and NF-κB signalling function". PLOS ONE 16, n.º 11 (4 de noviembre de 2021): e0259556. http://dx.doi.org/10.1371/journal.pone.0259556.
Texto completoTeramachi, Jumpei, Kyaw Ze Yar Myint, Rentian Feng, Xiangqun Xie, Jolene J. Windle, David Roodman y Noriyoshi Kurihara. "Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells". Blood 118, n.º 21 (18 de noviembre de 2011): 888. http://dx.doi.org/10.1182/blood.v118.21.888.888.
Texto completoKurihara, Noriyoshi, Tadashi Honjo, Jolene J. Windle, J. Shin y G. D. Roodman. "Targeting p62ZIP in Marrow Stromal Cells Is Highly Effective at Inhibiting Myeloma Cell Growth and Osteoclast Formation." Blood 106, n.º 11 (16 de noviembre de 2005): 630. http://dx.doi.org/10.1182/blood.v106.11.630.630.
Texto completoKurihara, Noriyoshi, Y. Hiruma, J. Windle, C. S. Hong, J. Shin y David Roodman. "Targeting p62 in Marrow Stromal Cells Is Effective at Inhibiting Myeloma Cell Growth." Blood 108, n.º 11 (16 de noviembre de 2006): 513. http://dx.doi.org/10.1182/blood.v108.11.513.513.
Texto completoTeramachi, Jumpei, Jolene J. Windle, David Roodman y Noriyoshi Kurihara. "The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation". Blood 116, n.º 21 (19 de noviembre de 2010): 128. http://dx.doi.org/10.1182/blood.v116.21.128.128.
Texto completoLaurin, Nancy, Jacques P. Brown, Jean Morissette y Vincent Raymond. "Recurrent Mutation of the Gene Encoding sequestosome 1 (SQSTM1/p62) in Paget Disease of Bone". American Journal of Human Genetics 70, n.º 6 (junio de 2002): 1582–88. http://dx.doi.org/10.1086/340731.
Texto completoHiruma, Yuko, Noriyoshi Kurihara y David Roodman. "p62 Signaling Is Increased in Multiple Myeloma Microenvironment." Blood 110, n.º 11 (16 de noviembre de 2007): 669. http://dx.doi.org/10.1182/blood.v110.11.669.669.
Texto completoLiu, Chang, Yuan He, Xiaobing Xu y Baorong He. "Phospholipase Cγ Signaling in Bone Marrow Stem Cell and Relevant Natural Compounds Therapy". Current Stem Cell Research & Therapy 15, n.º 7 (14 de octubre de 2020): 579–87. http://dx.doi.org/10.2174/1574888x14666191107103755.
Texto completoHöppner, Jakob, Katja Steff, Felix Lobert, Christoph M. Heyer, Berthold P. Hauffa y Corinna Grasemann. "Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition". Hormone Research in Paediatrics 94, n.º 3-4 (2021): 151–58. http://dx.doi.org/10.1159/000517164.
Texto completoMannino, Federica y Post Doc. "ODP599 Modulation of Wnt/b-catenin and Autophagy in an in vitro Model of Glucocorticoid-induced Osteoporosis". Journal of the Endocrine Society 6, Supplement_1 (1 de noviembre de 2022): A186. http://dx.doi.org/10.1210/jendso/bvac150.384.
Texto completoSilbermann, Rebecca, Wei Zhao, Julie L. Eiseman, Jan H. Beumer, Xiang-Qun Xie, Peng Yang, Kyaw-Zeyar Myint et al. "A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo". Blood 122, n.º 21 (15 de noviembre de 2013): 684. http://dx.doi.org/10.1182/blood.v122.21.684.684.
Texto completoBorsani, Elisa, Veronica Bonazza, Barbara Buffoli, Pier Francesco Nocini, Massimo Albanese, Francesca Zotti, Francesco Inchingolo, Rita Rezzani y Luigi F. Rodella. "Beneficial Effects of Concentrated Growth Factors and Resveratrol on Human Osteoblasts In Vitro Treated with Bisphosphonates". BioMed Research International 2018 (2018): 1–13. http://dx.doi.org/10.1155/2018/4597321.
Texto completoSilbermann, Rebecca, Dan Zhou, Jumpei Teramachi, Xiang-Qun Xie, G. David Roodman y Noriyoshi Kurihara. "The p62-ZZ Domain Inhibitor XRK3F2 Alters Myeloma-Induced Suppression of Osteoblast Differentiation and Is Highly Cytotoxic to Myeloma Cells in Combination with Bortezomib". Blood 124, n.º 21 (6 de diciembre de 2014): 2083. http://dx.doi.org/10.1182/blood.v124.21.2083.2083.
Texto completoTeramachi, J., R. Silbermann, P. Yang, W. Zhao, K. S. Mohammad, J. Guo, J. L. Anderson et al. "Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo". Leukemia 30, n.º 2 (19 de agosto de 2015): 390–98. http://dx.doi.org/10.1038/leu.2015.229.
Texto completoWang, Shumin, Eri O. Maruyama, John Martinez, Justin Lopes, Trunee Hsu, Wencheng Wu, Wei Hsu y Takamitsu Maruyama. "MicroRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling". eLife 12 (8 de febrero de 2023). http://dx.doi.org/10.7554/elife.79768.
Texto completoOh, Sue Young, Namju Kang, Jung Yun Kang, Ki Woo Kim, Jong-Hoon Choi, Yu-Mi Yang y Dong Min Shin. "Sestrin2 Regulates Osteoclastogenesis via the p62-TRAF6 Interaction". Frontiers in Cell and Developmental Biology 9 (26 de marzo de 2021). http://dx.doi.org/10.3389/fcell.2021.646803.
Texto completoQin, Huan, Wenwen Zhao, Yang Jiao, Haoyi Zheng, Hao Zhang, Jingyu Jin, Qiu Li, Xiuping Chen, Xia Gao y Yantao Han. "Aqueous Extract of Salvia miltiorrhiza Bunge-Radix Puerariae Herb Pair Attenuates Osteoporosis in Ovariectomized Rats Through Suppressing Osteoclast Differentiation". Frontiers in Pharmacology 11 (21 de enero de 2021). http://dx.doi.org/10.3389/fphar.2020.581049.
Texto completoWen, Cailing, Yuheng Zhou, Yanting Xu, Huijing Tan, Caixia Pang, Haiqian Liu, Kaifei Liu et al. "The Regulatory Role of GBF1 on Osteoclast Activation Through EIF2a Mediated ER Stress and Novel Marker FAM129A Induction". Frontiers in Cell and Developmental Biology 9 (25 de agosto de 2021). http://dx.doi.org/10.3389/fcell.2021.706768.
Texto completoLi, Jie, Xinle Li, Daquan Liu, Kazunori Hamamura, Qiaoqiao Wan, Sungsoo Na, Hiroki Yokota y Ping Zhang. "eIF2α signaling regulates autophagy of osteoblasts and the development of osteoclasts in OVX mice". Cell Death & Disease 10, n.º 12 (diciembre de 2019). http://dx.doi.org/10.1038/s41419-019-2159-z.
Texto completoLi, Mengye, Shengxiang Fu, Zhongyuan Cai, Danyang Li, Li Liu, Di Deng, Rongrong Jin y Hua Ai. "Dual regulation of osteoclastogenesis and osteogenesis for osteoporosis therapy by iron oxide hydroxyapatite core/shell nanocomposites". Regenerative Biomaterials 8, n.º 5 (9 de agosto de 2021). http://dx.doi.org/10.1093/rb/rbab027.
Texto completoCheng, Cheng, Lan Weiss, Henri Leinonen, Alyaa Shmara, Hong Z. Yin, Timothy Ton, Annie Do et al. "VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy". Journal of Translational Medicine 20, n.º 1 (8 de enero de 2022). http://dx.doi.org/10.1186/s12967-021-03186-6.
Texto completo